Abstract
The ingestion of antimicrobial residues in foods of animal origin has the potential risk of exposing colonic bacteria to small concentrations of antibiotics and inducing resistance in the colonic bacteria. To investigate whether human intestinal contents would influence resistance development in bacteria, Escherichia coli ATCC 25922 (MIC of enrofloxacin <0.03 μg ml−1) was exposed to 0.01 to 1 μg ml−1 of enrofloxacin in media supplemented with glucose, sucrose, sodium acetate or sterilized human fecal extract. In the first passage, only the medium containing sterilized fecal extract supported the growth of E. coli at an enrofloxacin concentration equal to the MIC. In the second and third passages following exposure to sub-inhibitory concentrations of the drug, the bacteria in media containing sterilized fecal extract grew at 0.1 μg ml−1 of enrofloxacin. The efflux pump inhibitors, reserpine and carbonyl cyanide-m-chlorophenylhydrazone (CCCP), increased the sensitivity of bacteria to 0.1 μg ml−1 of enrofloxacin in the medium containing sucrose, but their effect was not observed in the medium supplemented with 2.5% sterilized fecal extract. The proportions of unsaturated and saturated fatty acids in E. coli grown in the medium with 2.5% sterilized fecal extract differed from those grown in the medium alone. Fecal extract may contain unknown factors that augment the ability of E. coli to grow in concentrations of enrofloxacin higher than MIC, both in the presence and absence of efflux pump inhibitors. This is the first study showing that fecal extract affects the level of sensitivity of E. coli to antimicrobial agents.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Cerniglia, C. E. & Kotarski, S. Evaluation of veterinary drug residues in food for their potential to affect human intestinal microflora. Regul. Toxicol. Pharmacol. 29, 238–261 (1999).
Cerniglia, C. E. & Kotarski, S. Approaches in the safety evaluations of veterinary antimicrobial agents in food to determine the effects on the human intestinal microflora. J. Vet. Pharmacol. Ther. 28, 3–20 (2005).
Cho, H. J. et al. Monitoring of fluoroquinolone residual levels in chicken eggs by microbiological assay and confirmation by liquid chromatography. Biomed. Chromatogr. 22, 92–99 (2008).
Reyes-Herrera, I. & Donoghue, D. J. Antibiotic residues distribute uniformly in broiler chicken breast muscle tissue. J. Food Prot. 71, 223–5 (2008).
Donoghue, D. J., Reyes-Herrera, I., Schneider, M. J. & Blore, P. J. The relationship between blood and muscle samples to monitor for residues of the antibiotic enrofloxacin in chickens. Poult. Sci. 90, 481–485 (2011).
Angulo, F. J., Nargund, V. N. & Chiller, T. C. Evidence of an association between use of anti-microbial agents in food animals and anti-microbial resistance among bacteria isolated from humans and the human health consequences of such resistance. J. Vet. Med. Series B-Infect. Dis. Vet. Public Health 51, 374–379 (2004).
Carman, R. J. et al. Antibiotics in the human food chain: Establishing no effect levels of tetracycline, neomycin, and erythromycin using a chemostat model of the human colonic microflora. Regul. Toxicol. Pharmacol. 43, 168–180 (2005).
Perrin-Guyomard, A. et al. Impact of ciprofloxacin in the human-flora-associated (HFA) rat model: Comparison with the HFA mouse model. Regul. Toxicol. Pharmacol. 45, 66–78 (2006).
Silley, P. Impact of antimicrobial residues on gut communities: are the new regulations effective? J. Appl. Microbiol. 102, 1220–1226 (2007).
Finlay, B. B. et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect. Immun. 79, 1536–1545 (2011).
EMA. The European Agency for the Evaluation of Medicinal products. Enrofloxacin (modification for bovine, porcine and poultry). EMEA/MRL/388/98-Final. Available at: 〈www.ema.europa.eu/pdfs/vet/mrls/038898en.pdf〉 (1998).
Joint FAO/WHO Expert Committee on Food Additives (JECFA). Evaluation of Certain Veterinary Drug Residues in Food: Forty-eight Meeting of the Joint FAO/WHO Expert Committee on Food Additives. WHO technical Report Series No. 39.: Geneva, Switzerland (1997).
Willmott, C. J. R. & Maxwell, A. A single point mutation in the DNA gyrase-a protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother. 37, 126–127 (1993).
Vila, J. et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichiacoli and MICs. Antimicrob. Agents Chemother. 38, 2477–2479 (1994).
Ouabdesselam, S., Hooper, D. C., Tankovic, J. & Soussy, C. J. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichiacoli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by 2 different single gyrA mutations. Antimicrob. Agents Chemother. 39, 1667–1670 (1995).
Everett, M. J., Jin, Y. F., Ricci, V. & Piddock, L. J. V. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40, 2380–2386 (1996).
Miyamae, S., Nikaido, H., Tanaka, Y. & Yoshimura, F. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 42, 2119–2121 (1998).
Oethinger, M., Kern, W. V., Jellen-Ritter, A. S., McMurry, L. M. & Levy, S. B. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. 44, 10–13 (2000).
Piddock, L. J. V., White, D. G., Gensberg, K., Pumbwe, L. & Griggs, D. J. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 44, 3118–3121 (2000).
Coldham, N. G., Webber, M., Woodward, M. J. & Piddock, L. J. V. A 96-well plate fluorescence assay for assessment of cellular permeability and active efflux in Salmonella enterica serovar Typhimurium and Escherichia coli. J. Antimicrob. Chemother. 65, 1655–1663 (2010).
Stephen, A. M. & Cummings, J. H. The microbial contribution to human faecal mass. J. Med. Microbiol. 13, 45–56 (1980).
Wagman, G. H., Bailey, J. V. & Weinstein, M. J. Binding of aminoglycosides to feces. Antimicrob. Agents Chemother. 6, 415–7 (1974).
Hazenberg, M. P., Pennock-Schroder, A. M., Van den Boom, M. & Van de Merwe, J. P. Binding to and antibacterial effect of ampicillin, neomycin and polymyxin B on human feces. J. Hyg. Camb 93, 27–34 (1984).
Veringa, E. M. & van der Waaij, D. Biological inactivation by feces of antimicrobial drugs applicable in selective decontamination of the digestive tract. J. Antimicrob. Chemother. 14, 605–612 (1984).
De Vries-Hospers, H., Jansen, G., Tonk, R., Oenema, D. & van der Waaij, D. The in vitro inactivation of thirteen beta-lactam antibiotics by other mechanisms than adsorption to faecal substance. Infection 21, 127–130 (1993).
Van Saene, J. J. M., van Saene, H. K. F. & Lerk, C. F. Inactivation of quinolones. J Infect. Dis 153, 999–1000 (1986).
Costons, G.M.P.J., Bos, L. P., Engels, L.G.J.B. & Janson, P. C. W. A new method for chemical analysis of faeces. Clinica Chimica Acta 150, 197–203 (1985).
Pasquali, F. & Manfreda, G. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa. Vet. Microbiol. 119, 304–310 (2007).
Eaves, D. J., Liebana, E., Woodward, M. J. & Piddock, L. J. V. Detection of gyrA mutations in quinolone-resistant Salmonella enterica by denaturing high-performance liquid chromatography. J. Clin. Microbiol. 40, 4121–4125 (2002).
Tamura, K., Dudley, J., Nei, M. & Kumar, S. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol. Biol.Evol. 24, 1596–1599 (2007).
Chapman, J. S. & Georgopapadakou, N. H. Fluorometric assay for fleroxacin uptake by bacterial-cells. Antimicrob. Agents Chemother. 33, 27–29 (1989).
Rafii, F., Park, M. & Wynne, R. Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi. Chemotherapy 51, 256–262 (2005).
Song, B., Palleroni, N. J., Kerkhof, L. J. & Häggblom, M. M. Characterization of halobenzoate-degrading, denitrifying Azoarcus and Thauera isolates and description of Thauera chlorobenzoica sp. nov. Int. J. Syst. Evol. Microbiol. 51, 589–602 (2001).
Kamberi, M. et al. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. Antimicrob. Agents Chemother. 43, 525–529 (1999).
Costongs, G.M.P.J., Bos, L. P., Engels, L.G.J.B. & Janson, P. C. W. A new method for chemical-analysis of feces. Clin. Chim. Acta 150, 197–203 (1985).
Aristilde, L. & Sposito, G. Binding of ciprofloxacin by humic substances: A molecular dynamics study. Environ. Toxicol. Chem. 29, 90–98 (2010).
Hao, W- L. & Lee, Y- K. Microflora of the gastrointestinal tract: A review. Methods Mol. Biol. 268, 491–502 (2004).
Cook, T. M., Brown, K. G., Boyle, J. V. & Goss, W. A. Bactericidal action of nalidixic acid on Bacillus subtilis. J. Bacteriol. 92, 1510–1514 (1966).
Li, Q. X., Bi, X. M., Diao, Y. J. & Deng, X. M. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens. Am. J. Vet. Res. 68, 812–815 (2007).
Sinensky, M. Homeoviscous adaptation—a homeostatic process that regulates the viscosity of membrane lipids in Escherichia coli. Proc. Natl Acad. Sci. USA 71, 522–525 (1974).
Russell, N. J. & Fukunaga, N. A comparison of thermal adaptation of membrane lipids in psychrophilic and thermophilic bacteria. FEMS Microbiol. Rev. 75, 171–182 (1990).
Mejỳa, R., Gomez-Eichelmann, M. C. & Fernandez, M. S. Membrane fluidity of Escherichia coli during heat-shock. Biochem. Biophys. Acta 1239, 195–200 (1995).
Catry, B. et al. Antimicrobial resistance patterns of Escherichia coli through the digestive tract of veal calves. Microb. Drug Resist. -Mechanisms Epidemiol. Disease 13, 147–150 (2007).
Acknowledgements
We thank Donald Paine for providing bacterial strains, Hyeri Ahn, Monica Yun and Inhae Sung for technical assistance, and Dr John B Sutherland and Dr Bruce D Erickson for reviewing the manuscript. The views presented in this article do not necessarily reflect those of the Food and Drug Administration.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ahn, Y., Sung, K., Rafii, F. et al. Effect of sterilized human fecal extract on the sensitivity of Escherichia coli ATCC 25922 to enrofloxacin. J Antibiot 65, 179–184 (2012). https://doi.org/10.1038/ja.2012.1
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2012.1
